Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Whilst tremendous advances have been made in the treatment of coronary artery disease, hypertension, and heart failure, the optimal management of atrial fibrillation (AF) still remains a challenge. Furthermore, the prevalence of AF is increasing in developed countries due to aging of the general population, and this arrhythmia affects more than 8% of patients over 80 years of age.
Treatment of AF has two major goals: symptom relief and prevention of complications such as thromboembolic events and heart failure. Given that AF commonly co-exists with multiple co-morbidities — essentially cardiovascular risk factors — there is no surprise that sub-optimal control of cardiovascular risk factors translates to the subsequent development of AF. Also, AF leads to an increased risk of mortality and hospitalizations, the latter resulting in a high healthcare cost burden.[4,5] Hospitalizations are also a surrogate for subsequent mortality in AF patients.
Nonetheless, AF represents a maj ...
- Lip GY, Tse HF. Management of atrial fibrillation. Lancet 2007; 370: 604–18. CrossRef
- Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042–6. CrossRef
- Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123: 1501–8. CrossRef
- Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003; 108: 711–6. CrossRef
- Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004; 90: 286–92. CrossRef
- Friberg L, Rosenqvist M. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: report from the Stockholm Cohort Study of Atrial Fibrillation. Europace 2011; 13: 626–33. CrossRef
- Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at ‘moderate risk’ [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103: 683–5. CrossRef
- Kumana CR, Cheung BM, Cheung GT, et al. Rhythm vs. rate control of atrial fibrillation meta-analysed by number needed to treat. Br J Clin Pharmacol 2005; 60: 347–54. CrossRef
- Testa L, Biondi-Zoccai GG, Dello Russo A, et al. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J 2005; 26: 2000–6. CrossRef
- de Denus S, Sanoski CA, Carlsson J, et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005; 165: 258–62. CrossRef
- Corley SD, Epstein AE, DiMarco JP, et al., AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004; 109: 1509–13. CrossRef
- Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc 2009; 84: 234–42. CrossRef
- Pamukcu B, Lip GY. Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice. Expert Opin Pharmacother 2011; 12: 131–40. CrossRef
- Singh BN, Connolly SJ, Crijns HJ, et al., EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357: 987–99. CrossRef
- Køber L, Torp-Pedersen C, McMurray JJ, et al., Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678–87. CrossRef
- Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21: 597–605. CrossRef
- Hohnloser SH, Crijns HJ, van Eickels M, et al., ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668–78. CrossRef
- Connolly SJ, Crijns HJ, Torp-Pedersen C, et al., ATHENA Investigators. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009; 120: 1174–80. CrossRef
- Dagres N, Varounis C, Iliodromitis EK, et al. Impact of dronedarone on the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials. Am J Cardiovasc Drugs 11 (5): ((to come)).
- Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score= 1. Thromb Haemost 2010; 103(4): 833–40. CrossRef
- Mazzaglia G, Filippi A, Alacqua M, et al. A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thromb Haemost 2010; 103(5): 968–75. CrossRef
American Journal of Cardiovascular Drugs
Volume 11, Issue 6 , pp 355-356
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links